These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 14716771

  • 1. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F, Terruzzi E, Perego D, Miccolis I, Rivolta F, Manca E, Pogliani EM.
    Cancer; 2004 Jan 15; 100(2):350-5. PubMed ID: 14716771
    [Abstract] [Full Text] [Related]

  • 2. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ.
    Zhonghua Zhong Liu Za Zhi; 2007 May 15; 29(5):391-5. PubMed ID: 17892140
    [Abstract] [Full Text] [Related]

  • 3. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A, Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G, Pogliani E.
    Haematologica; 1995 May 15; 80(4):318-24. PubMed ID: 7590500
    [Abstract] [Full Text] [Related]

  • 4. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 15; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 5. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A.
    Cancer; 2005 Mar 01; 103(5):970-7. PubMed ID: 15666323
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P.
    J Clin Oncol; 2003 Jun 01; 21(11):2115-22. PubMed ID: 12775737
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A, García EL, Fernández R, Gonzalez JL, Neri N, Díaz-Maqueo JC.
    Ann Hematol; 2002 Jul 01; 81(7):368-73. PubMed ID: 12185505
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B, French GOELAMS Group.
    Haematologica; 2005 Jun 01; 90(6):802-9. PubMed ID: 15951293
    [Abstract] [Full Text] [Related]

  • 9. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM.
    Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A, Tatsumi Y, Tanaka K, Yasui Y, Inoue T.
    Anticancer Res; 1999 Dec 15; 19(4C):3393-7. PubMed ID: 10629625
    [Abstract] [Full Text] [Related]

  • 11. Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas.
    Gopal R, Nair R, Saikia TK, Soman CS, Dinshaw KA, Advani SH.
    J Assoc Physicians India; 1994 Oct 15; 42(10):781-4. PubMed ID: 7533151
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM.
    Cancer; 1999 Oct 01; 86(7):1368-76. PubMed ID: 10506727
    [Abstract] [Full Text] [Related]

  • 13. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M, Wittebol S, Budel LM, Uyl-de Groot CA, Kramer MH.
    Ned Tijdschr Geneeskd; 2004 Jan 10; 148(2):88-93. PubMed ID: 14753131
    [Abstract] [Full Text] [Related]

  • 14. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):847-52. PubMed ID: 15465202
    [Abstract] [Full Text] [Related]

  • 15. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B.
    J Clin Oncol; 2005 Jun 20; 23(18):4117-26. PubMed ID: 15867204
    [Abstract] [Full Text] [Related]

  • 16. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    Economopoulos T, Dimopoulos MA, Mellou S, Pavlidis N, Samantas E, Nicolaides C, Tsatalas C, Papadopoulos A, Papageogriou E, Papasavvas P, Fountzilas G.
    Eur J Haematol; 2002 Mar 20; 68(3):135-43. PubMed ID: 12068793
    [Abstract] [Full Text] [Related]

  • 17. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY, Xu RH, He YJ, Guan ZZ.
    Ai Zheng; 2003 Apr 20; 22(4):393-6. PubMed ID: 12703996
    [Abstract] [Full Text] [Related]

  • 18. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.
    J Clin Oncol; 2005 Mar 20; 23(9):1984-92. PubMed ID: 15668467
    [Abstract] [Full Text] [Related]

  • 19. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.
    Cancer; 2004 Dec 15; 101(12):2788-801. PubMed ID: 15481055
    [Abstract] [Full Text] [Related]

  • 20. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
    Abate G, Tafuto S, Romano A, Gailli E, Corazzelli G.
    Haematologica; 1992 Dec 15; 77(4):322-5. PubMed ID: 1385277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.